The DOI matches its Crossref record; 446 of the 446 references it cites were found in a registry or an index.
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer
Abstract
Cancer is the second leading cause of human death globally. PI3K/Akt/mTOR signaling is one of the most frequently dysregulated signaling pathways observed in cancer patients that plays crucial roles in promoting tumor initiation, progression and therapy responses. This is largely due to that PI3K/Akt/mTOR signaling is indispensable for many cellular biological processes, including cell growth, metastasis, survival, metabolism, and others. As such, small molecule inhibitors targeting major kinase components of the PI3K/Akt/mTOR signaling pathway have drawn extensive attention and been developed and evaluated in preclinical models and clinical trials. Targeting a single kinase component within this signaling usually causes growth arrest rather than apoptosis associated with toxicity-induced adverse effects in patients. Combination therapies including PI3K/Akt/mTOR inhibitors show improved patient response and clinical outcome, albeit developed resistance has been reported. In this review, we focus on revealing the mechanisms leading to the hyperactivation of PI3K/Akt/mTOR signaling in cancer and summarizing efforts for developing PI3K/Akt/mTOR inhibitors as either mono-therapy or combination therapy in different cancer settings. We hope that this review will facilitate further understanding of the regulatory mechanisms governing dysregulation of PI3K/Akt/mTOR oncogenic signaling in cancer and provide insights into possible future directions for targeted therapeutic regimen for cancer treatment, by developing new agents, drug delivery systems, or combination regimen to target the PI3K/Akt/mTOR signaling pathway. This information will also provide effective patient stratification strategy to improve the patient response and clinical outcome for cancer patients with deregulated PI3K/Akt/mTOR signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Items 401–446 of 446
Bartlett, J. M. S. (2010) · Clinical Breast Cancer · doi:10.3816/cbc.2010.s.017 · Cited by 28
Baird, R. D., van Rossum, A. G. J., Oliveira, M., Beelen, K. J., Gao, M., Schrier, M., Mandjes, I. A. M., García-Corbacho, J., Vallier, A.-L., Dougall, G., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0508 · Cited by 28
Li, Q., Lai, Z., Yan, Z., Peng, J., Jin, Y., Wei, L., & Lin, J. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7903 · Cited by 27
Wu, B., Li, A., Zhang, Y., Liu, X., Zhou, S., Gan, H., Cai, S., Liang, Y., & Tang, X. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1730809 · Cited by 27
Marks, D. K., Gartrell, R. D., Asmar, M. E., Boboila, S., Hart, T. D., Lu, Y., Pan, Q., Yu, J., Hibshoosh, H. H., Guo, H., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00968 · Cited by 27
Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss
Owusu‐Brackett, N., Zhao, M., Akçakanat, A., Evans, K. W., Yuca, E., Dumbrava, E. I., Jankú, F., & Meric‐Bernstam, F. (2020) · Oncotarget · doi:10.18632/oncotarget.27503 · Cited by 26
MAGI3–AKT3 fusion in breast cancer amended
Mosquera, J., Varma, S., Pauli, C., MacDonald, T. Y., Yashinskie, J. J., Varga, Z., Sboner, A., Moch, H., Rubin, M. A., & Shin, S. J. (2015) · Nature · doi:10.1038/nature14265 · Cited by 25
Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis
Mancini, M., Lien, E. C., & Toker, A. (2016) · Oncotarget · doi:10.18632/oncotarget.8191 · Cited by 25
Koh, K. X., Tan, G. H., Low, S. H. H., Omar, M. F. M., Han, M. J., Iacopetta, B. J., Soo, R. A., Beloueche‐Babari, M., Bhattacharya, B., & Soong, R. (2017) · Oncotarget · doi:10.18632/oncotarget.22655 · Cited by 25
Calleros, L., Sánchez-Hernández, I., Baquero, P., Toro, M. J., & Chiloeches, A. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp188 · Cited by 24
Gene amplification of ribosomal protein S6 kinase-1 and -2 in gastric cancer.
Yoshida, S., MATSUMOTO, K. Y., Arao, T., Taniguchi, H., Goto, I., Hanafusa, T., Nishio, K., & Yamada, Y. (2013) · PubMed · Cited by 23
Shamieh, S. E., Saleh, F., Moussa, S., Kattan, J. G., & Farhat, F. S. (2018) · Pharmacogenomics · doi:10.2217/pgs-2018-0019 · Cited by 23
Wang, M., Li, J., Huang, J., & Luo, M. (2020) · BioMed Research International · doi:10.1155/2020/1598037 · Cited by 23
Waetzig, R., Matthes, M., Leister, J., Penkivech, G., Heise, T., Corbacioglu, S., & Sommer, G. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.48393 · Cited by 23
Liu, X., Xu, Y., Wang, Y., Chen, Y., Wang, B.-B., Wang, Y., Chen, Y., Tan, C., Hu, L.-D., Ma, Q., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.07.011 · Cited by 22
Chang, J., Ling, H., Liu, Y., Pan, Y., Yang, H., Ye, W., Xu, K., Li, Z., & Zhang, S. (2020) · Cancer Management and Research · doi:10.2147/cmar.s250171 · Cited by 21
Gao, L., Liu, J., Xu, P., Deng, G., Liu, B., Yuan, F., Tan, Y., Sun, Q., Xu, Y., Zhang, H., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01102 · Cited by 20
Wang, W.-F., Xie, Y., Zhou, Z.-H., Qin, Z., Wu, J., & He, J. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.163 · Cited by 19
Goodwin, C. B., Yang, Z., Yin, F., Yu, M., & Chan, R. J. (2012) · Haematologica · doi:10.3324/haematol.2011.046896 · Cited by 19
Yokota, T., Serizawa, M., Hosokawa, A., Kusafuka, K., Mori, K. P., Sugiyama, T., Tsubosa, Y., & Koh, Y. (2018) · BMC Cancer · doi:10.1186/s12885-018-4733-7 · Cited by 18
Trivedi, N., Armstrong, S. A., Wang, H., Hartley, M. L., Deeken, J. F., He, A. R., Subramaniam, D. S., Melville, H., Albanese, C., Marshall, J. L., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.3672 · Cited by 18
Clinicopathological Significance of Elevated PIK3CA Expression in Gastric Cancer
Jang, S., Kim, K.-J., Oh, M., Lee, J., Lee, H. J., Cho, H. D., Han, S. W., Son, M. W., & Lee, M. S. (2016) · Journal of the Korean Gastric Cancer Association · doi:10.5230/jgc.2016.16.2.85 · Cited by 17
Analysis of TSC1 mutation spectrum in mucosal melanoma
Ma, M., Dai, J., Xu, T., Yu, S., Yu, H., Tang, H., Yan, J., Wu, X., Yu, J., Chi, Z., et al. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2550-z · Cited by 17
Experimental Approaches in Delineating mTOR Signaling
Qian, J., Su, S., & Liu, P. (2020) · Genes · doi:10.3390/genes11070738 · Cited by 17
Self-citationCopanlisib in the treatment of non-Hodgkin lymphoma
Narkhede, M. S., & Cheson, B. D. (2020) · Future Oncology · doi:10.2217/fon-2020-0195 · Cited by 17
AKT1E17K Is Oncogenic in Mouse Lung and Cooperates with Chemical Carcinogens in Inducing Lung Cancer
Malanga, D., Belmonte, S., Colelli, F., Scarfò, M., Marco, C. D., Oliveira, D. M., Mirante, T., Camastra, C., Gagliardi, M., Rizzuto, A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147334 · Cited by 16
Inhibition of MAPK pathway is essential for suppressing Rheb-Y35N driven tumor growth
Wang, Y., Hong, X., Wang, J., Yin, Y., Zhang, Y., Zhou, Y., Piao, H.-L., Liang, Z., Zhang, L., Li, G., et al. (2016) · Oncogene · doi:10.1038/onc.2016.246 · Cited by 16
Rashid, M. M., Lee, H., & Jung, B. H. (2017) · Journal of Chromatography B · doi:10.1016/j.jchromb.2017.11.027 · Cited by 16
Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer
Petrossian, K., Nguyen, D. M., Lo, C., Kanaya, N., Somlo, G., Cui, Y. X., Huang, C., & Chen, S. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4779-x · Cited by 16
Slotkin, E. K., Diolaiti, D., Shukla, N. N., Cruz, F. S. D., Clark, J., Gundem, G., Yellapantula, V. D., Levine, M. F., You, D., Ma, P., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0953 · Cited by 16
toosi, B., Zaker, F., Alikarami, F., Kazemi, A., & Ardestani, M. T. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.03.009 · Cited by 15
Liu, S., Tang, Y., Yan, M., & Jiang, W. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0563-3 · Cited by 15
HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological features
Ding, Q., Chen, H., Lim, B., Damodaran, S., Chen, W., Tripathy, D., Piha-Paul, S. A., Luthra, R., Meric‐Bernstam, F., & Şahin, A. A. (2019) · Human Pathology · doi:10.1016/j.humpath.2019.07.006 · Cited by 14
Wang, Y., Zhang, X., Ma, Q., Hu, L., Zhang, X., Wang, Y., Xu, L., Yang, C., Tan, C., Kong, X., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-020-03370-4 · Cited by 14
Wang, S., Liu, M., Lian, S., Liu, N., Zhang, G., Zhao, Q., Zhang, Y., & Jian, L. (2020) · BioMed Research International · doi:10.1155/2020/7451576 · Cited by 13
Zhang, J., Guo, J., Qin, X., Wang, B., Zhang, L., Wang, Y., Gan, W., Pandolfi, P. P., Chen, W., & Wei, W. (2018) · Science Signaling · doi:10.1126/scisignal.aao1052 · Cited by 11
Two novel TSC2 mutations in pediatric patients with tuberous sclerosis complex
Gao, S., Wang, Z., & Xie, Y. (2018) · Medicine · doi:10.1097/md.0000000000011533 · Cited by 11
Zhang, X., Duan, Y., Wang, Y., Zhao, X., Sun, Y.-M., Lin, D., Chen, Y., Wang, Y., Zhou, Z., Liu, Y.-X., et al. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00644-1 · Cited by 11
Occurrence of low frequency PIK3CA and AKT2 mutations in gastric cancer
Zhang, Q.-Y., Cheng, W., Li, W.-M., Au, W. W., & Lu, Y. (2014) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2014.07.007 · Cited by 10
TSC2 rare germline variants in non-tuberous sclerosis patients with neuroendocrine neoplasias
Asprino, P. F., Linck, R. D. M., Cesar, J. E. D. S., Freitas, F. P., Koyama, F. C., Riechelmann, R. P., Costa, F. P., Hoff, P. M., Galante, P. A. F., Meyer, D., et al. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0286 · Cited by 9
Heard, J. J., Phung, I., Potes, M. I., & Tamanoi, F. (2018) · BMC Cancer · doi:10.1186/s12885-017-3938-5 · Cited by 9
STAT3‐mediated MLST8 gene expression regulates cap‐dependent translation in cancer cells
Lee, H., Chin, H., Kim, H., Jung, H., & Lee, D. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12735 · Cited by 9
Soliman, G. A., Shukla, S. K., Etekpo, A., Gunda, V., Steenson, S., Gautam, N., Alnouti, Y., & Singh, P. K. (2020) · Current Developments in Nutrition · doi:10.1093/cdn/nzaa131 · Cited by 9
Winn Aung, U., Tsuji, A. B., Sudo, H., Sugyo, A., Ukai, Y., Kouda, K., Kurosawa, Y., Furukawa, T., Saga, T., & Higashi, T. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i42.7551 · Cited by 8
Associations of PIK3CA Mutations with Clinical Features and Prognosis in Gastric Cancer
Shen, X., Zhao, Y., Chen, X., Sun, H., Liu, M., Zhang, W., Jiang, F., & Li, P. (2019) · Future Oncology · doi:10.2217/fon-2018-0335 · Cited by 7
Jiangyi, W., Guo, G., Guohai, S., & Ye, D. (2020) · Aging · doi:10.18632/aging.102654 · Cited by 6
Cited by
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Advances in the role of STAT3 in macrophage polarization
Xia, T., Zhang, M., Lei, W., Yang, R., Fu, S., Fan, Z., Yang, Y., & Zhang, T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1160719 · Cited by 284
Crosstalk between circRNAs and the PI3K/AKT signaling pathway in cancer progression
Xue, C., Li, G., Lu, J., & Li, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00788-w · Cited by 268
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Tomuleasa, C., Tigu, A.-B., Munteanu, R., Moldovan, C.-S., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H., & Croce, C. M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01899-w · Cited by 260
Chen, G., Zhang, H., Sun, H., Ding, X., Liu, G., Yang, F., Feng, G., Dong, X., Zhu, Y., Wang, X., et al. (2023) · Apoptosis · doi:10.1007/s10495-023-01855-z · Cited by 47
Metadata
- Authors
- Yu, L., Wei, J., & Liu, P.
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2022-10
- Volume
- 85
- Pages
- 69-94
- ISSN
- 1044-579X (ISSN-L)
- OpenAlex
- W3176165488
- Cited by
- 763
- References
- 446
- FWCI
- 23.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.